ACM Global Relocates to Expanded Lab Facilities in Europe
ACM Global Central Laboratory
, the central laboratory that continually defines the customer-service standard with its flexible approach, today announced that it has relocated its laboratory facilities in York, England. The move to a larger facility is in response to growing client demand for ACM Global’s clinical trials testing services throughout Europe, including Western and Eastern Europe, as well as South Africa and the Middle East.
The new, state-of-the-art facility offers 14,500 square feet of laboratory and office space, nearly twice the size of ACM Global’s previous facility in York, and accommodates ACM Global’s expanding laboratory operations as well as its growing staff of data analysts, project managers and quality assurance specialists.
“Our new facility enables us to continue our growth in the European market and to expand the menu of clinical trials testing services we offer our clients,” said Jerry Boxall, Managing Director, Europe at ACM Global Central Laboratory. “We are excited with the prospects offered by our new facility, which has been purpose-built to optimize our laboratory processes. The additional space enhances our ability to continue to meet the needs of our clients with high-quality laboratory services, while positioning us to take advantage of new opportunities in the market.”
“Expansion of our European laboratory hub represents a significant investment by our company, driven by our growth over the last several years”, said Angela J. Panzarella, President of ACM Medical Laboratory, Incorporated, the parent company of ACM Global Central Laboratory. “We have enjoyed robust growth in our European and global business, and the new facility represents our commitment to the region and to continuous improvement of the services we offer our clients.”
To celebrate its new laboratory location, ACM Global will host a grand opening and ribbon-cutting event on Thursday, January 17, 2013 at the new facility, located at 23 Hospital Fields Road in York. Current and prospective clients are invited to attend the day-long event, which will include tours of the facility, a workshop and an evening reception. For questions regarding the relocation or to attend the grand opening, please visit
http://www.acmgloballab.com/yorkrelocationfaq.aspx
.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
